Pimecrolimus 1% Cream in the Treatment of Facial Psoriasis: A 16-Week Open-Label Study

@article{Jacobi2008Pimecrolimus1C,
  title={Pimecrolimus 1\% Cream in the Treatment of Facial Psoriasis: A 16-Week Open-Label Study},
  author={Arnd Jacobi and Matthias Dr Braeutigam and Vera Mahler and Erwin S. Schultz and Michael Hertl},
  journal={Dermatology},
  year={2008},
  volume={216},
  pages={133 - 136}
}
Background: Facial psoriasis requires a treatment approach other than topical corticosteroids which bear the risk of skin atrophy. Topical pimecrolimus has been shown to be effective in atopic eczema and recently in psoriasis. Objective: The aim of this open-label single-center investigator-initiated study was to evaluate the efficacy and safety of pimecrolimus 1% cream in patients with facial psoriasis. Methods: 20 adults with facial psoriasis were enrolled. Pimecrolimus 1% cream was applied… 

Figures and Tables from this paper

Is pimecrolimus cream (1%) an appropriate therapeutic agent for the treatment of external ear atopic dermatitis?

The results clearly demonstrate that 1% pimecrolimus cream can be an effective alternative therapeutic agent in cases where steroid treatment proves to be insufficient or in casesWhere treatment must be discontinued due to its adverse effects.

Pimecrolimus Cream 1% for the Treatment of Papulopustular Eruption Related to Epidermal Growth Factor Receptor Inhibitors: A Case Series and a Literature Review of Therapeutic Approaches

The case series shows that pimecrolimus cream may be an effective and safe approach in the management of papulopustular eruption related to EGFRIs.

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway

Tailored recommendations are given for the topical management of specific areas (scalp, facial, intertriginous/genital, or palmoplantar lesions), certain symptoms (hyperkeratotic or hyperinflammatory forms) as well as during pregnancy or a period of breastfeeding.

Treatment of Localized Vitiligo with 1% Pimecrolimus Cream versus 0.05% Clobetasol Propionate Cream—Single, Blinded, Comparative Therapeutic Trial

Topical 1% pimecrolimus is as effective as clobetasol propionate in treatment of localized vitiligo affecting less than 5% of the body surface area but pime crolimus was more preferred as the side effects of topical steroid could be avoided.

Innovative use of topical calcineurin inhibitors.

  • A. Lin
  • Medicine
    Dermatologic clinics
  • 2010

Pimecrolimus for psoriasis

A comprehensive review of the literature on topical and oral Pimecrolimus and its utility in the treatment of patients with psoriasis following literature searches via PubMed and Embase is provided.

Efficacy of Topical Calcineurin Inhibitors in Psoriasis

  • Cong WangA. Lin
  • Medicine, Biology
    Journal of cutaneous medicine and surgery
  • 2014
The evidence (double-blind and open studies) is strong that topical tacrolimus and, to a lesser extent, pimecrolimus have efficacy in the treatment of psoriasis.

Optimizing topical therapy for psoriasis

There are a wide variety of topical treatment options for psoriasis and topical vitamin D analogs and other noncorticosteroid agents can be used as complements to optimize long-term results.

Formulation and Evaluation of Topical Gel Containing Azithromycin and Prednisolone Vesicles for Treating Psoriasis

Gels prepration of azithromycin and pr ednisolone are more effective in reduction of purit ies, scaling and hyperkeratosis of psoriasis plaque due to high entrapment efficiency and stability.

Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails

The need to individualize treatment strategies for psoriasis based on the area of the body that is affected and the emerging role of biologic therapy in this regard is highlighted.

References

SHOWING 1-10 OF 35 REFERENCES

Pimecrolimus 1 percent cream in the treatment of psoriasis in a child.

The efficacy of twice daily application of pimecrolimus 1 percent cream in a girl who suffered from psoriasis involving the eyelids and anogenital region is reported, and the plaques completely resolved.

Occlusive Treatment of Chronic Hand Dermatitis with Pimecrolimus Cream 1% Results in Low Systemic Exposure, Is Well Tolerated, Safe, and Effective

Twice daily topical treatment of moderate to severe chronic hand dermatitis with pimecrolimus cream 1% results in low pime crolimus blood levels, is well tolerated, safe, and effective.

Topical tacrolimus: an effective therapy for facial psoriasis.

Topical tacrolimus is an effective treatment for facial psoriasis without occlusion and a complete or good response was obtained in 10 and 9 patients, respectively.

Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.

Pimecrolimus cream 1% appears to be a safe and effective alternative to currently used therapies for AD and atopic dermatitis in children and adults.

Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study.

Calcipotriol ointment, applied twice daily, had a better effect than tacrolimus ointsment and placebo ointments once daily in the treatment of psoriasis, and there was no statistically significant difference between the efficacy of tacolimus and placebo Ointment.

Tacrolimus ointment in the treatment of eyelid dermatitis.

Tacrolimus ointment 0.1% may be a safe and effective treatment option for patients with moderate to severe eyelid dermatitis and the physician global assessment (PGA) of eyelid clinical response.

Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.

Tacrolimus 0.1% ointment may be a safe and effective treatment option for patients with psoriasis on the face, intertriginous areas, or both.

Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas.

Limited application of fluticasone propionate ointment over a period of 10 weeks is effective and delays lesion recurrence without causing skin atrophy in patients with moderate to severe psoriasis in areas at risk for corticosteroid application, such as facial and intertriginous areas.